Menjugate vaccine recall in the UK attracts widespread publicity
This article was originally published in Scrip
Novartis has recalled two batches of the meningitis vaccine, Menjugate Kit (meningococcal group C conjugate vaccine) in the UK as a precautionary measure. A sterility failure in a batch of solvent used in the vaccines was found during non-routine testing. The UK regulator, the MHRA, has instituted a class 2 alert, with action to be taken within 48 hours.
You may also be interested in...
Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.